Get the Stockscreener App
204.28
1.80%
3.61
After Hours:
203.01
-1.27
-0.62%
Natera Inc stock is traded at $204.28, with a volume of 1.29M.
It is up +1.80% in the last 24 hours and up +18.21% over the past month.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
See More
Previous Close:
$200.67
Open:
$196.27
24h Volume:
1.29M
Relative Volume:
1.11
Market Cap:
$28.04B
Revenue:
$1.96B
Net Income/Loss:
$-253.24M
P/E Ratio:
-107.45
EPS:
-1.9012
Net Cash Flow:
$94.06M
1W Performance:
+2.36%
1M Performance:
+18.21%
6M Performance:
+34.98%
1Y Performance:
+35.19%
1-Day Range:
$195.14
$205.80
1-Week Range:
$195.14
$212.21
52-Week Range:
$125.38
$212.21
Natera Inc Stock (NTRA) Company Profile
Name
Natera Inc
Sector
Industry
Phone
650-249-9090
Address
13011 MCCALLEN PASS, AUSTIN, CA
Compare NTRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NTRA
Natera Inc
|
204.28 | 27.70B | 1.96B | -253.24M | 94.06M | -1.9012 |
|
TMO
Thermo Fisher Scientific Inc
|
578.71 | 217.96B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
221.21 | 156.24B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
689.93 | 56.01B | 4.17B | 1.03B | 940.22M | 12.61 |
|
A
Agilent Technologies Inc
|
146.82 | 41.64B | 6.79B | 1.22B | 1.09B | 4.2644 |
|
IQV
Iqvia Holdings Inc
|
220.61 | 38.07B | 15.90B | 1.28B | 2.21B | 7.2842 |
Natera Inc Stock (NTRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-27-25 | Upgrade | BNP Paribas Exane | Underperform → Neutral |
| Sep-22-25 | Resumed | Wells Fargo | Equal Weight |
| Mar-13-25 | Initiated | RBC Capital Mkts | Outperform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-08-24 | Resumed | Craig Hallum | Buy |
| Feb-20-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-29-23 | Reiterated | BTIG Research | Buy |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Nov-13-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-28-23 | Initiated | Bernstein | Mkt Perform |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-05-23 | Initiated | UBS | Buy |
| Jan-18-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Apr-25-22 | Initiated | Stephens | Overweight |
| Mar-08-22 | Initiated | Goldman | Buy |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| May-25-21 | Initiated | Wells Fargo | Overweight |
| Jan-28-21 | Initiated | Truist | Buy |
| Oct-08-20 | Initiated | BTIG Research | Buy |
| Sep-28-20 | Initiated | Morgan Stanley | Overweight |
| Sep-17-20 | Initiated | SVB Leerink | Outperform |
| Jun-10-20 | Resumed | Piper Sandler | Overweight |
| May-07-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-05-18 | Initiated | JP Morgan | Neutral |
| Jul-05-18 | Reiterated | Piper Jaffray | Overweight |
| Aug-07-17 | Reiterated | Morgan Stanley | Overweight |
| Nov-10-16 | Reiterated | The Benchmark Company | Buy |
| May-23-16 | Reiterated | The Benchmark Company | Buy |
| May-11-16 | Reiterated | The Benchmark Company | Buy |
| Apr-19-16 | Initiated | The Benchmark Company | Buy |
| Sep-28-15 | Upgrade | Wedbush | Neutral → Outperform |
| Aug-14-15 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-04-15 | Initiated | Robert W. Baird | Outperform |
| Jul-27-15 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-27-15 | Initiated | Piper Jaffray | Overweight |
| Jul-27-15 | Initiated | Wedbush | Neutral |
View All
Natera Inc Stock (NTRA) Latest News
How Natera Inc. stock reacts to bond yieldsWeekly Profit Report & Long-Term Safe Return Strategies - newser.com
Is Natera Inc. stock entering bullish territoryJuly 2025 Institutional & Accurate Technical Buy Alerts - newser.com
Can momentum traders help lift Natera Inc.July 2025 Rallies & Long Hold Capital Preservation Plans - newser.com
Is Natera Inc. stock a defensive play in 2025Risk Management & Free High Accuracy Swing Entry Alerts - newser.com
How to integrate Natera Inc. into portfolio analysis toolsAnalyst Upgrade & Accurate Intraday Trade Tips - newser.com
Will Natera Inc. stock beat EPS estimates2025 Institutional Moves & Long Hold Capital Preservation Plans - newser.com
Ranking Natera Inc. among high performing stocks via toolsProfit Target & Fast Moving Trade Plans - newser.com
How high can Natera Inc. stock go2025 Market Overview & Risk Managed Trade Strategies - newser.com
Does Natera (NTRA) Have a Long Runway For Growth? - Insider Monkey
Stephens Reaffirms Their Buy Rating on Natera (NTRA) - The Globe and Mail
Natera co-founder Sheena Jonathan sells $903k in stock By Investing.com - Investing.com South Africa
Automated trading signals detected on Natera Inc.Earnings Risk Summary & Expert Curated Trade Setup Alerts - newser.com
Published on: 2025-11-05 02:57:17 - newser.com
Natera price target raised to $235 from $17 at Stephens - TipRanks
NTRA: Stephens & Co. Raises Price Target on Natera to $235 | NTR - GuruFocus
Natera stock price target raised to $235 from $197 at Stephens - Investing.com
Natera Integrates with Flatiron Health’s OncoEMR® Platform - BioSpace
Natera at UBS Global Healthcare Conference: Strategic Growth and Future Prospects - Investing.com Nigeria
Natera co-founder Sheena Jonathan sells $903k in stock - Investing.com India
Natera Integrates Oncology Testing into Flatiron’s OncoEMR® to Streamline Cancer Care - HIT Consultant
Natera at UBS Global Healthcare Conference: Strategic Growth and Future Prospects By Investing.com - Investing.com South Africa
Natera, Inc. Integrates with Flatiron Health?S Oncoemr Platform - MarketScreener
Natera Integrates Oncology Tests With Flatiron's Electronic Medical Record Platform - MarketScreener
Natera (NTRA) Is Up 5.2% After Raising 2025 Revenue Guidance and Expanding Women’s Health Portfolio - simplywall.st
Natera announces data from PROCEED-CRC trial - MSN
Natera price target raised to $230 from $220 at Piper Sandler - TipRanks
NTRA: Piper Sandler Raises Price Target to $230, Maintains Overw - GuruFocus
Natera (NTRA): Valuation Insights Following Strong Q3 Results and Upbeat Guidance Boost - Yahoo Finance
Natera stock reaches all-time high at 203.78 USD By Investing.com - Investing.com Nigeria
Natera (NTRA) Q3 2025 Earnings Call Transcript - AOL.com
Natera Inc Stock (NTRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):